JP2023504016A5 - - Google Patents

Info

Publication number
JP2023504016A5
JP2023504016A5 JP2022530837A JP2022530837A JP2023504016A5 JP 2023504016 A5 JP2023504016 A5 JP 2023504016A5 JP 2022530837 A JP2022530837 A JP 2022530837A JP 2022530837 A JP2022530837 A JP 2022530837A JP 2023504016 A5 JP2023504016 A5 JP 2023504016A5
Authority
JP
Japan
Prior art keywords
cancer
bcma
cdr
polypeptide chain
chain comprises
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022530837A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023504016A (ja
JP7773466B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2020/131767 external-priority patent/WO2021104371A1/en
Publication of JP2023504016A publication Critical patent/JP2023504016A/ja
Publication of JP2023504016A5 publication Critical patent/JP2023504016A5/ja
Priority to JP2024185441A priority Critical patent/JP7847630B2/ja
Application granted granted Critical
Publication of JP7773466B2 publication Critical patent/JP7773466B2/ja
Priority to JP2026063021A priority patent/JP2026108862A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022530837A 2019-11-26 2020-11-26 Cd3およびbcmaに対する抗体およびそれらから作製した二重特異性結合タンパク質 Active JP7773466B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024185441A JP7847630B2 (ja) 2019-11-26 2024-10-21 Cd3およびbcmaに対する抗体およびそれらから作製した二重特異性結合タンパク質
JP2026063021A JP2026108862A (ja) 2019-11-26 2026-04-07 Cd3およびbcmaに対する抗体およびそれらから作製した二重特異性結合タンパク質

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2019120991 2019-11-26
CNPCT/CN2019/120991 2019-11-26
CN2020111796 2020-08-27
CNPCT/CN2020/111796 2020-08-27
PCT/CN2020/131767 WO2021104371A1 (en) 2019-11-26 2020-11-26 Antibodies to cd3 and bcma, and bispecific binding proteins made therefrom

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024185441A Division JP7847630B2 (ja) 2019-11-26 2024-10-21 Cd3およびbcmaに対する抗体およびそれらから作製した二重特異性結合タンパク質

Publications (3)

Publication Number Publication Date
JP2023504016A JP2023504016A (ja) 2023-02-01
JP2023504016A5 true JP2023504016A5 (cg-RX-API-DMAC7.html) 2023-12-01
JP7773466B2 JP7773466B2 (ja) 2025-11-19

Family

ID=76130007

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2022530837A Active JP7773466B2 (ja) 2019-11-26 2020-11-26 Cd3およびbcmaに対する抗体およびそれらから作製した二重特異性結合タンパク質
JP2024185441A Active JP7847630B2 (ja) 2019-11-26 2024-10-21 Cd3およびbcmaに対する抗体およびそれらから作製した二重特異性結合タンパク質
JP2026063021A Pending JP2026108862A (ja) 2019-11-26 2026-04-07 Cd3およびbcmaに対する抗体およびそれらから作製した二重特異性結合タンパク質

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024185441A Active JP7847630B2 (ja) 2019-11-26 2024-10-21 Cd3およびbcmaに対する抗体およびそれらから作製した二重特異性結合タンパク質
JP2026063021A Pending JP2026108862A (ja) 2019-11-26 2026-04-07 Cd3およびbcmaに対する抗体およびそれらから作製した二重特異性結合タンパク質

Country Status (11)

Country Link
US (1) US20230002489A1 (cg-RX-API-DMAC7.html)
EP (2) EP4065164A4 (cg-RX-API-DMAC7.html)
JP (3) JP7773466B2 (cg-RX-API-DMAC7.html)
KR (2) KR20240162588A (cg-RX-API-DMAC7.html)
CN (1) CN114728065A (cg-RX-API-DMAC7.html)
AU (2) AU2020390288A1 (cg-RX-API-DMAC7.html)
CA (1) CA3160163A1 (cg-RX-API-DMAC7.html)
IL (2) IL293138A (cg-RX-API-DMAC7.html)
MX (2) MX2022006230A (cg-RX-API-DMAC7.html)
TW (1) TWI774137B (cg-RX-API-DMAC7.html)
WO (1) WO2021104371A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014374055B2 (en) * 2013-12-30 2018-11-08 Epimab Biotherapeutics Inc. Fabs-in-tandem immunoglobulin and uses thereof
IL300760A (en) * 2020-08-24 2023-04-01 Epimab Biotherapeutics Hk Ltd Anti-ROR1 antibodies and related bispecific binding proteins
US20250051443A1 (en) * 2021-10-07 2025-02-13 National Research Council Of Canada Anti-cd3 monoclonal antibodies and therapeutic constructs
CN116375868A (zh) * 2021-12-31 2023-07-04 康源博创生物科技(北京)有限公司 一种抗cd3的人源化抗体及其在制备双特异性抗体中的应用
CN117003871A (zh) 2022-04-28 2023-11-07 北京天广实生物技术股份有限公司 结合bcma和cd3的抗体及其用途
WO2024012513A1 (en) * 2022-07-13 2024-01-18 Hansoh Bio Llc Antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
WO2024074145A1 (zh) * 2022-10-08 2024-04-11 盛禾(中国)生物制药有限公司 一种结合baffr和cd3的双特异性抗体及其应用
CN120418284A (zh) * 2022-12-19 2025-08-01 和铂医药(上海)有限责任公司 “κ/λ” Fab-Fab串联多特异性结合蛋白及其制备和应用
EP4719352A1 (en) 2023-05-31 2026-04-08 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
CN117024596B (zh) * 2023-08-18 2024-02-27 镜像绮点(上海)细胞技术有限公司 肿瘤原代细胞特异性标记与活体成像
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025131077A1 (zh) * 2023-12-21 2025-06-26 上海君实生物医药科技股份有限公司 抗cd3多特异性抗体及用途
WO2025168059A1 (zh) * 2024-02-08 2025-08-14 天劢源和生物医药(上海)有限公司 靶向bcma、cd19和cd3的多特异性抗原结合蛋白及其应用
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
FI903489A7 (fi) 1988-11-11 1990-07-10 Medical Res Council Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
NZ537277A (en) 2002-07-18 2008-04-30 Crucell Holland Bv Recombinant production of mixtures of antibodies
US8236308B2 (en) 2005-10-11 2012-08-07 Micromet Ag Composition comprising cross-species-specific antibodies and uses thereof
EP2714737A1 (en) 2011-05-27 2014-04-09 Glaxo Group Limited Bcma (cd269/tnfrsf17) -binding proteins
JP6636803B2 (ja) 2013-02-05 2020-01-29 エンクマフ エスアーエールエル Bcmaに対する抗体の選択のための方法
HUE050159T2 (hu) * 2013-12-17 2020-11-30 Genentech Inc Anti-CD3 antitestek és alkalmazási eljárások
AU2014374055B2 (en) * 2013-12-30 2018-11-08 Epimab Biotherapeutics Inc. Fabs-in-tandem immunoglobulin and uses thereof
EP2982692A1 (en) 2014-08-04 2016-02-10 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
EP3023437A1 (en) * 2014-11-20 2016-05-25 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
HUE057285T2 (hu) * 2015-04-13 2022-04-28 Pfizer Terápiás ellenanyagok és alkalmazásaik
EP3310811B1 (en) * 2015-06-16 2021-06-16 Genentech, Inc. Anti-cd3 antibodies and methods of use
JP7014724B2 (ja) * 2016-02-06 2022-02-01 エピムアブ バイオセラピューティクス インコーポレイテッド タンデム型Fab免疫グロブリンおよびその使用
IL299221A (en) * 2016-06-21 2023-02-01 Teneobio Inc Cd3 binding antibodies
CA3032430A1 (en) * 2016-08-16 2018-02-22 Epimab Biotherapeutics, Inc. Monovalent asymmetric tandem fab bispecific antibodies
WO2018224441A1 (en) * 2017-06-05 2018-12-13 Numab Innovation Ag Novel anti-cd3 antibodies
CN109535257B (zh) * 2017-09-22 2021-05-28 同润生物医药(上海)有限公司 新型双特异性cd3/cd19多肽复合物
EP3732199A1 (en) * 2017-12-27 2020-11-04 TeneoBio, Inc. Cd3-delta/epsilon heterodimer specific antibodies
CN112074541A (zh) * 2018-05-03 2020-12-11 上海岸迈生物科技有限公司 Pd-1和lag-3的高亲和力抗体以及由其制备的双特异性结合蛋白
WO2019220368A1 (en) * 2018-05-16 2019-11-21 Janssen Biotech, Inc. Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy

Similar Documents

Publication Publication Date Title
JP2021522347A5 (cg-RX-API-DMAC7.html)
JP2023538945A5 (cg-RX-API-DMAC7.html)
JP2023002615A5 (cg-RX-API-DMAC7.html)
JP2021534096A5 (cg-RX-API-DMAC7.html)
JP2022515318A5 (cg-RX-API-DMAC7.html)
JP2021522162A5 (cg-RX-API-DMAC7.html)
JP2021530251A5 (cg-RX-API-DMAC7.html)
JP2018503380A5 (cg-RX-API-DMAC7.html)
JP2021501162A5 (cg-RX-API-DMAC7.html)
JP2024056687A5 (cg-RX-API-DMAC7.html)
JP2020522254A5 (cg-RX-API-DMAC7.html)
JP2018522888A5 (cg-RX-API-DMAC7.html)
JP2018523493A5 (cg-RX-API-DMAC7.html)
RU2018146050A (ru) Биспецифические связывающие белки, которые связывают иммуномодулирующий белок и опухолевый антиген
RU2018106452A (ru) Поливалетные и полиспецифичные gitr-связывающие слитые белки
JP2021508707A5 (cg-RX-API-DMAC7.html)
JP2017535257A5 (cg-RX-API-DMAC7.html)
JP2021520832A5 (cg-RX-API-DMAC7.html)
JP2018507188A5 (cg-RX-API-DMAC7.html)
JP2020516240A5 (cg-RX-API-DMAC7.html)
JP2020533016A5 (cg-RX-API-DMAC7.html)
JP2023545521A5 (cg-RX-API-DMAC7.html)
JP2021531255A5 (cg-RX-API-DMAC7.html)
JP2023509214A5 (cg-RX-API-DMAC7.html)
JP2023549316A5 (cg-RX-API-DMAC7.html)